Patients with haematological malignancies now have access to CAR-T therapy which has dramatically improved outcomes
CAR-T therapy is associated with significant toxicities, but with supportive management mortality is low
Initial presentation of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome can be non-specific, and a broad differential must be managed in the first instance
Low grade CRS and ICANS may be managed with supportive measures alone
High grade CRS can be treated with an IL-6 receptor antagonist, tocilizumab
High grade ICANS is treated with immunosuppression, with steroids being the mainstay of treatment
